Worth Leon J, Seymour John F, Slavin Monica A
Centre for Clinical Research Excellence in Infectious Disease, Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Victoria, 3052, Australia.
Support Care Cancer. 2009 Jul;17(7):811-8. doi: 10.1007/s00520-008-0561-7. Epub 2008 Dec 19.
Central venous catheter (CVC)-related bloodstream infection (CR-BSI) is a significant complication in hematology patients. A range of CVC devices may be used, and risks for the development of complications are not uniform. The objectives of this study were to determine the natural history and rate of CVC-related complications and risk factors for CR-BSI and to compare device-specific complications in a hematology population.
An observational cohort of patients with hematologic malignancy was prospectively studied following CVC insertion. Participants were reviewed until a CVC-related complication necessitated device removal, completion of therapy, death, or defined end-of-study date. The National Nosocomial Infection Surveillance definition for CR-BSI was used. Overall and device-specific rates of infective and noninfective complications were calculated and potential risk factors were captured.
One hundred six CVCs (75 peripherally inserted central venous catheters [PICCs], 31 nontunneled CVCs) were evaluated in 66 patients, over 2,399 CVC days. Thrombosis occurred in 16 cases (15.1%), exit-site infection in two (1.9%), and CR-BSI in 18 (7.5 per 1,000 CVC days). No significant differences were found when complication rates in PICC and nontunneled devices were compared. An underlying diagnosis of acute myeloid leukemia was negatively associated with CR-BSI (odds ratio (OR) 0.14, p = 0.046), and a previous diagnosis of fungal infection was associated with infection (OR 22.82, p = 0.031).
CR-BSI rates in our hematology population are comparable to prior reports. A low rate of exit-site infection and high proportion of thrombotic complications were observed. No significant differences in thrombotic or infective complications were evident when PICC and nontunneled devices were compared. PICC devices are a practical and safe option for management of hematology patients.
中心静脉导管(CVC)相关血流感染(CR-BSI)是血液学患者的一种严重并发症。可使用多种CVC装置,发生并发症的风险并不一致。本研究的目的是确定CVC相关并发症的自然史、发生率以及CR-BSI的危险因素,并比较血液学人群中特定装置的并发症。
对血液系统恶性肿瘤患者在插入CVC后进行前瞻性观察队列研究。对参与者进行随访,直至出现与CVC相关的并发症而需要拔除导管、完成治疗、死亡或达到规定的研究结束日期。采用国家医院感染监测定义来诊断CR-BSI。计算感染性和非感染性并发症的总体发生率及特定装置发生率,并记录潜在危险因素。
对66例患者的106根CVC(75根经外周静脉穿刺中心静脉导管[PICC],31根非隧道式CVC)进行了评估,总计2399个CVC日。发生血栓形成16例(15.1%),出口部位感染2例(1.9%),CR-BSI 18例(每1000个CVC日7.5例)。比较PICC和非隧道式装置的并发症发生率时,未发现显著差异。急性髓系白血病的潜在诊断与CR-BSI呈负相关(比值比[OR]0.14,p = 0.046),既往真菌感染诊断与感染相关(OR 22.82,p = 0.031)。
我们血液学人群中的CR-BSI发生率与既往报道相当。观察到出口部位感染发生率低,血栓形成并发症比例高。比较PICC和非隧道式装置时,血栓形成或感染性并发症无明显差异。PICC装置是血液学患者管理的一种实用且安全的选择。